Upcoming strategies for the treatment of metastatic melanoma. (Q37986477)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350184%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

title

Upcoming strategies for the treatment of metastatic melanoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350184%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350184%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

Paola Queirolo

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350184%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

author name string

Francesco Spagnolo

series ordinal

1

1 reference

26 August 2017

Paola Queirolo

series ordinal

2

1 reference

26 August 2017

17 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350184%20AND%20SRC:MED&resulttype=core&format=json

Archives of Dermatological Research

23 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350184%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

volume

304

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350184%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

page(s)

177-184

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350184%20AND%20SRC:MED&resulttype=core&format=json

23 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22350184%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00403-012-1223-7

23 January 2020

exact match

0 references

cites work

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

KIT gene mutations and copy number in melanoma subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Raf: a strategic target for therapeutic development against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

KIT as a therapeutic target in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

BRAF as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Major response to imatinib mesylate in KIT-mutated melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Improved endpoints for cancer immunotherapy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Phase II trial of imatinib mesylate in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Large-scale analysis of KIT aberrations in Chinese patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Incidence of noncutaneous melanomas in the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Targeted molecular therapy in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Cyclin D3 expression in melanoma cells is regulated by adhesion-dependent phosphatidylinositol 3-kinase signaling and contributes to G1-S progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Use of DNA microarray and small animal positron emission tomography in preclinical drug evaluation of RAF265, a novel B-Raf/VEGFR-2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Lack of clinical efficacy of imatinib in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-012-1223-7